Adjuvant vemurafenib in resected, BRAFV600 mutation-positive melanoma (BRIM8): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trialMichele Maio, Bohuslav Melichar, Karl D. Lewis et al.|The Lancet Oncology|2018Cited by 216
Outcome after PORT in ypN2 or R1/R2 versus no PORT in ypN0 Stage III-N2 NSCLC after Induction Chemotherapy and ResectionCharlotte Billiet, Dirk De Ruysscher, Christophe Dooms et al.|Journal of Thoracic Oncology|2016Cited by 25